Cost-effectiveness analysis: Cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 2, 2011, Pages 243-251

  Saini, S D ^a,b,c   Fendrick, A M ^b   Scheiman, J M ^b  

^a HSR and D Center of Excellence   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PROTON PUMP INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG WITHDRAWAL; DYSPEPSIA; HEART INFARCTION; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK REDUCTION; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

EID: 79960256684     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04707.x     Document Type: Article

References (57)

1. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-72. (Pubitemid 43947981)
2. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113: 203-12.
3. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED,. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006; 151: 185-91. (Pubitemid 41815352)
4. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L,. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003; 145: 438-44. (Pubitemid 36390489)
5. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-74. (Pubitemid 44729867)
6. Burger W, Chemnitius JM, Kneissl GD, Rucker G,. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 2005; 257: 399-414. (Pubitemid 40604544)
7. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152: 1-9.
8. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313-6. (Pubitemid 18042841)
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
10. Tournoij E, Peters RJ, Langenberg M, Kanhai KJ, Moll FL,. The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis. Eur J Vasc Endovasc Surg 2009; 37: 597-603.
11. Melloni C, Alexander KP, Ou FS, et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. The American Journal of Cardiology 2009; 104: 175-81.
12. Spiegel BM, Farid M, Dulai GS, Gralnek IM, Kanwal F,. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. The American Journal of Medicine 2006; 119: 448-e27.
13. Saini SD, Schoenfeld P, Fendrick AM, Scheiman J,. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med 2008; 168: 1684-90.
14. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M,. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011; 171: 218-25.
15. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Eng J Med 2000; 343: 834-9.
16. Serrano P, Lanas A, Arroyo MT, Ferreira IJ,. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002; 16: 1945-53.
17. Derry S, Loke YK,. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ (Clinical research ed) 2000; 321: 1183-7.
18. Laine L,. Review article: gastrointestinal bleeding with low-dose aspirin-what's the risk? Aliment Pharmacol Ther 2006; 24: 897-908. (Pubitemid 44326371)
19. McQuaid KR, Laine L,. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. The American Journal of Medicine 2006; 119: 624-38. (Pubitemid 44128438)
20. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. The American Journal of Cardiology 2005; 95: 1218-22. (Pubitemid 40616424)
21. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP,. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010; 32: 1240-8.
22. Hernandez-Diaz S, Garcia Rodriguez LA,. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Medicine 2006; 4: 22.
23. Rockall TA, Logan RF, Devlin HB, Northfield TC,. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. Br Med J (Clin Res Ed) 1995; 311: 222-6.
24. Rockall TA, Logan RF, Devlin HB, Northfield TC,. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316-21. (Pubitemid 26074312)
25. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Eng J Med 2005; 352: 238-44. (Pubitemid 40110812)
26. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Eng J Med 2002; 346: 2033-8. (Pubitemid 34680594)
27. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. The American Journal of Gastroenterology 2007; 102: 507-15. (Pubitemid 46328156)
28. Ng FH, Wong BC, Wong SY, Chen WH, Chang CM,. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk-a single-blind, randomized controlled study. Aliment Pharmacol Ther 2004; 19: 359-65. (Pubitemid 38253511)
29. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
30. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139: 272-81. (Pubitemid 30090804)
31. Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH,. Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study. Arch Intern Med 1994; 154: 2649-57.
32. Sud A, Kline-Rogers EM, Eagle KA, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother 2005; 39: 1792-7. (Pubitemid 41527689)
33. Newby LK, Bhapkar MV, White HD, et al. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. J Thromb Thrombolysis 2003; 16: 119-28. (Pubitemid 39137437)
34. de Gaetano G,. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95.
35. Pradhan AD, Cook NR, Manson JE, Ridker PM, Buring JE,. A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. Diabetes Care 2009; 32: 3-8.
36. Wei L, Fahey T, MacDonald TM,. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. Br J Clin Pharmacol 2008; 66: 110-6. (Pubitemid 351822170)
37. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503. (Pubitemid 47212371)
38. Cannon CP, Rhee KE, Califf RM, et al. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). The American Journal of Cardiology 2010; 105: 445-52.
39. Healthcare Cost and Utilization Project. Available at:. Accessed January 22, 2010.
40. Red Book. Montvale, NJ: Thomson Healthcare, Inc., 2009.
41. Briggs AH, Claxton K, Sculpher MJ,. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006.
42. Collet JP, Himbet F, Steg PG,. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000; 76: 257-8.
43. Ferrari E, Benhamou M, Cerboni P, Marcel B,. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-9. (Pubitemid 40186800)
44. Eagle KA, Koelling TM, Montoye CK,. Primer: implementation of guideline-based programs for coronary care. Nat Clin Pract Cardiovasc Med 2006; 3: 163-71.
45. Ellerbeck EF, Kresowik TF, Hemann RA, Mason P, Wiblin RT, Marciniak TA,. Impact of quality improvement activities on care for acute myocardial infarction. Int J Qual Health Care 2000; 12: 305-10. (Pubitemid 30663849)
46. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998; 279: 1351-7. (Pubitemid 28198801)
47. Yang YX, Lewis JD, Epstein S, Metz DC,. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53. (Pubitemid 46021498)
48. Laine L,. Proton pump inhibitors and bone fractures? The American Journal of Gastroenterology 2009; 104 (Suppl 2): S21-6.
49. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD,. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179: 319-26.
50. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J,. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-5. (Pubitemid 46762758)
51. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010; 170: 765-71.
52. Targownik LE, Lix LM, Leung S, Leslie WD,. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896-904.
53. Leonard J, Marshall JK, Moayyedi P,. Systematic review of the risk of enteric infection in patients taking acid suppression. The American Journal of Gastroenterology 2007; 102: 2047-56. (Pubitemid 47301504)
54. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN,. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006; 43: 1272-6. (Pubitemid 44706452)
55. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA,. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170: 772-8.
56. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
57. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010; 122: 2619-33.